limited, the prevalence in different ethnic groups appears to be comparable. 7 Von Willebrand disease occurs equally in both sexes.
Three main types. Von Willebrand disease is classified into three major categories. These distinctions are based on pathophysiologic mechanisms (rather than on specific laboratory findings) and are useful in determining treatment regimens. Type 1 involves a partial quantitative deficiency of VWF; type 2 involves a qualitative defect in VWF; and type 3 involves a total deficiency of VWF. 1, 2 Appreciating the different types of von Willebrand disease can result in better understanding and management.
Approximately 75% of people with von Willebrand disease have type 1, which is characterized by mild-to-moderate bleeding; some people with this type may be asymptomatic. 2 People with type 1 have a decreased amount of normally functioning VWF; however, in some cases, mutations may also cause the VWF to clear from the circulation more rapidly than normal. The latter dysfunction is more common in people with blood type O. 2 Type 1 is suspected when VWF levels are only slightly below normal or in the lower end of the normal range, but in such cases diagnosis may be more difficult to confirm. bleeding episode occurs and isn't treated appropriately, the disorder can be fatal.
In adolescent girls and women, the most common symptom is menorrhagia, which may not seem unusual, especially if other family members have the disorder. In boys and men, the most common symptoms are bruising from even minor injuries and bleeding gums (girls and women may have these symptoms also). But because girls past the age of menarche and women who aren't yet menopausal regularly experience menses, the disorder can be more problematic for them than for boys and men. Although this article has relevance for any patient with von Willebrand disease, the primary focus is on the disorder in females.
PATHOPHYSIOLOGY
Von Willebrand disease was first described by the Finnish physician Erik von Willebrand in 1926. The disorder is caused by genetic defects in the concentration, structure, or function of von Willebrand factor (VWF), a protein needed for blood to clot. 1 VWF is synthesized and stored in the vascular epithelium and the bone marrow and excreted on demand when a vascular injury occurs. VWF assists in clot formation by providing an adhesive link between platelets and the subendothelium in the injured vessel wall (see Figure 1 ). VWF also transports factor VIII (FVIII), a protein necessary for clot stabilization. Thus a defect in VWF causes increased bleeding because of impaired platelet adhesion or reduced availability of FVIII (or both). 2 The amount of circulating VWF varies over the course of a lifetime and is influenced by various factors. This variability can complicate the diagnosis and management of von Willebrand disease. In healthy people, the range for circulating VWF is quite broad (50 to 200 IU/dL, measured using VWF antigen [VWF:Ag]). 2 Moreover, plasma levels increase with age; during pregnancy (up to five times the normal level by the third trimester); with systemic inflammation; and with acute stress (such as that associated with surgery, strenuous exercise, or anxiety), which triggers VWF release from the vascular endothelium. 2, 3 A traumatic blood draw that exposes the specimen to tissue factor and the activation of clotting factors can falsely elevate VWF levels. 2 Other factors that can raise VWF levels include taking estrogen or oral contraceptives 2 and smoking (smoking cessation appears to result in decreased VWF). Prevalence. Von Willebrand disease is less well known than hemophilia, another inherited bleeding disorder; yet it's much more common. Although estimates vary, the prevalence is believed to be as high as 1.3% of the U.S. population, or more than 4 million people. 2, 5, 6 Though studies in diverse populations are Almost all of the remaining 25% of people with von Willebrand disease have type 2.
2 They may have a normal or only slightly decreased amount of VWF, but their VWF has a qualitative defect. There are four variants of type 2, as determined by the specific type of VWF dysfunction. Type 2 is generally characterized by moderate bleeding, although there is considerable variation. Because of differences in how the variants of type 2 manifest, people with type 2 can have "strikingly distinct and specific therapeutic needs"; for help with disease management, the National Heart, Lung, and Blood Institute (NHLBI) advises referral to a hematologist with expertise in hemostasis. 2 Type 3, which is characterized by "undetectable" levels of VWF, is rare and often can be isolated to specific families. 2 People with type 3 often experience episodes of severe bleeding, and some have severe allergic reactions to blood products, making disease management especially challenging.
Heritability. Type 1 and most variants of type 2 can be inherited from either parent, while one variant of type 2 and type 3 require inheritance from both parents. 2 But an individual's symptoms may not be the same as those experienced by the affected parent. Moreover, although some people with von Willebrand disease are asymptomatic, they can still transmit the disorder to their children. These factors can also hamper disease recognition.
Acquired von Willebrand syndrome. There are also acquired disorders that mimic von Willebrand disease; these are known collectively as acquired von Willebrand syndrome. 1 The syndrome is rare and occurs most frequently in people with lymphoproliferative and myeloproliferative disorders such as lymphoma, leukemia, and myeloma; immunologic disorders; and cardiovascular disorders. 8 As with the inherited disease, acquired von Willebrand syndrome results from a defect in VWF concentration, structure, or function; is often not recognized; and results in prolonged or excessive bleeding.
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Sequelae of von Willebrand disease are related to excessive or prolonged bleeding and include chronic iron deficiency anemia, especially in premenopausal women. Girls and women with the disorder are also at increased risk for hemorrhagic ovarian cysts, endometriosis, and uterine leiomyomas (fibroids) as well as for complications during pregnancy and delivery, including spontaneous abortion and postpartum hemorrhage. 9 People who experience bleeding within their joints can develop chronic joint disease.
WHEN TO SUSPECT VON WILLEBRAND DISEASE
When a patient presents with a history of excessive bruising, one or more episodes of excessive or prolonged bleeding following minor injury, or menorrhagia, von Willebrand disease should be considered. The signs and symptoms are all associated with increased bleeding but vary depending on the type and the severity of the disorder. Besides those mentioned earlier, mild-to-moderate signs and symptoms in people with type 1 or type 2 may include a family history of a bleeding disorder, excessive or prolonged bleeding after dental procedures, one or more nosebleeds of more than 10 minutes' duration within the past year, and blood in the urine or stool. (For a comprehensive list, see Signs and Symptoms of von Willebrand Disease. 2, 9, 10 ) People with type 3 usually have one or more of these symptoms and may also have severe unexplained bleeding episodes. Without immediate treatment, these episodes can be fatal. People with type 3 are also more likely to experience bleeding into their joints or soft tissues (or both), causing severe pain and swelling.
Heavy menses at the onset of menarche is often the first sign of von Willebrand disease. 9 Although menorrhagia is common in women with the disorder, it is not a specific marker, since many women who don't have von Willebrand disease also report heavy menstrual bleeding. 2, 11 Moreover, the presence of menorrhagia can be difficult to establish, since patients and researchers tend to define the term differently. A common clinical definition is blood loss in excess of 80 mL per period. 12 Several clinical features have been found to consistently predict such loss. These include passing clots larger than one inch in diameter, low ferritin levels, anemia, soaking through tampons or pads more often than hourly, and soaking through bedclothes. 10, 12 A pictorial blood assessment chart (PBAC;
Signs and Symptoms of von Willebrand Disease 2, 9, 10
Type 1 or 2 is suggested by one or more of these:
• Family history of a bleeding disorder • Bruising (larger than 2 cm or with palpable lump) without notable injury • Prolonged bleeding (more than five minutes) following minor injury • One or more nosebleeds (generally bilateral) of more than 10 minutes' duration within the past year • Heavy or prolonged menses since menarche • Heavy menses that do not respond to conventional management • Unexpected bleeding after surgery • Hemorrhage requiring a blood transfusion • Oral bleeding without an obvious cause • Prolonged or excessive bleeding during or after dental procedures • Blood in urine or stool Type 3 is suggested by one or more of these:
• One or more of the signs and symptoms listed above • Severe unexplained bleeding • Unexplained bleeding into soft tissues or joints available free at http://bit.ly/wIo6cu) can be a helpful tool in evaluating menstrual blood loss. 13 A score of 100 or greater on the PBAC is also indicative of a bleeding disorder. 10, 13 Clinicians should consider the possibility of von Willebrand disease not only in patients who present with one or more signs and symptoms, but also in those with a history of excessive bleeding episodes who present for clearance before undergoing surgical or other invasive procedures.
INVESTIGATION AND DIAGNOSIS
When von Willebrand disease is suspected, it's essential to elicit a thorough history of any episodes of excessive or prolonged bleeding from both the patient and family members. The aforementioned list of signs and symptoms of the disease can be a useful guide in collecting initial historical information. Additionally, other areas to cover include 2 • the spontaneity, severity, and duration of bleeding episodes.
• bleeding sites.
• the ease or difficulty in stopping the bleeding.
• A thorough physical exam is also warranted, although it might not be particularly helpful if the patient hasn't had a recent bleeding episode. Assessment of the skin for bruising is important, as is assessment of the nasal, oral, and vaginal mucosa, because in people with von Willebrand disease these vulnerable areas may become reddened or bleed easily without a history of injury.
Further hematologic investigation is warranted to adequately evaluate the patient's VWF levels and function. Figure 2 2, 10 provides a guide for this investigation. There are several assays for von Willebrand disease, but they are expensive, so a provider might order just one or two. As noted above, 50 to 200 IU/dL is considered the normal VWF:Ag range.
2 When the VWF:Ag level is quite low-below 20 IU/dL-the patient will usually have VWF gene mutations, a "strongly positive family history," and significant bleeding symptoms.
2 When the VWF:Ag level is only slightly below normal or in the lower end of the normal range, von Willebrand disease may be suspected but is more difficult to establish. Research findings indicate that a majority of people with low normal or slightly below normal VWF:Ag levels have blood type O, and family inheritance patterns are often not as strong.
14 Two other tests are used to evaluate VWF function. 2, 3, 15 The VWF ristocetin cofactor activity (VWF: RCo) assay measures how well VWF functions in platelet adhesion. More recently, an enzyme-linked immunosorbent assay (ELISA) has been used to increase the sensitivity of this test (the new version is known as ELISA VWF:RCo). 15 The VWF collagenbinding ability (VWF:CB) assay measures the binding If the patient has a history of one or more of the following:
• One or more episodes of excessive bleeding (including uncontrolled heavy menses since menarche) Then:
• Consider other causes • Refer patient to appropriate specialist
If findings include either or both:
• Isolated PTT • One or more abnormal von Willebrand disease assay results CBC = complete blood count; FVIII = factor VIII; PT = prothrombin time; PTT = partial thromboplastin time; TT = thrombin time; VWF:Ag = von Willebrand factor antigen; VWF:RCo = von Willebrand factor ristocetin cofactor activity.
ajnonline.com of VWF to subendothelial collagen. Another test, the FVIII coagulant activity (FVIII:C) assay, evaluates the ability of VWF to protect FVIII from degradation. 15 During menstruation, estrogen and progesterone are at their lowest levels, as are VWF and FVIII levels. 16 Thus blood samples should be collected at this time. 10 However, a panel of international experts on von Willebrand disease, convened in 2007, agreed that in emergent cases, hematologic investigation should not be delayed. 10 If the patient isn't menstruating at the time of specimen collection and if her VWF and FVIII levels are slightly below or in the lower end of the normal range, repeat testing during menses could be helpful. Women with mild type 1 von Willebrand disease who are taking estrogen or oral contraceptives may have normal VWF and FVIII levels. However, discontinuing contraceptives is not recommended for testing. For such patients, testing can be done during the final week of the contraceptive cycle (when menses generally occur).
As noted above, people with blood type O may clear VWF from their circulation more rapidly than people with other blood types. According to the 2007 expert panel, however, blood type identification isn't necessary for evaluation or management of the disorder, since a deficiency of or defects in VWF causes bleeding symptoms regardless of blood type.
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Diagnosis. Making a diagnosis of types 2 and 3 von Willebrand disease is usually fairly straightforward, as it is based on abnormal laboratory values that indicate a defect in VWF activity. But diagnosing type 1, the most prevalent type, is often more challenging. People with type 1 may have low normal or slightly below normal levels of VWF, but generally there is no defect in VWF structure or function. Laboratory findings may reflect only subtle differences, and patients tend to have only a mild-to-moderate bleeding propensity. Thus the disorder is more likely to go unrecognized in people with type 1. For these individuals, it's particularly important to consider the aforementioned extraneous factors that can increase VWF plasma levels. If VWF levels are just below normal or in the lower end of the normal range, especially if any of these factors are present, repeating the laboratory tests might be helpful. Assistance from a hematologist with expertise in hemostasis is warranted, even when von Willebrand disease is suspec ted but the laboratory findings are inconclusive.
Diagnosing von Willebrand disease can be challenging for several other reasons. First, increased bleeding propensity may be caused by other diseases and conditions, such as hemophilia and certain auto immune or idiopathic disorders. Several common medications (such as NSAIDs, warfarin, clopidogrel, and heparin) have anticoagulant effects, and people taking these drugs often report bleeding episodes. (People with von Willebrand disease who are taking these medications may have even more dramatic bleeding episodes.) Because oral contraceptives can reduce bleeding propensity, detecting von Willebrand disease may be harder in women who are taking these drugs. 10 Also, because a battery of blood tests is required to evaluate VWF quantity and activity, and because repeat testing may be required, pursuing an investigation of possible von Willebrand disease can be expensive, especially if the tests are not covered by insurers.
MANAGEMENT
Management is aimed at preventing excessive bleeding and at stopping it when it occurs. Bleeding prophylaxis is especially important in patients with severe symptoms of von Willebrand disease. Beginning prophylaxis early in life can be effective in preventing long-term sequelae, especially arthropathy caused by bleeding into joints. 17 While various blood tests are useful in diagnosis, none is predictive of bleeding risk or which prophylaxis method might work best. Patient and family bleeding histories are much better indicators. 15 Since each patient's bleeding propensity is different, determining the best prophylaxis and treatment regimen is often challenging. A team approach to management, with assistance from appropriate specialists such as hematologists, pediatricians, and gynecologists, is recommended to ensure that the patient receives the best possible care. Other family members, especially children, should also be evaluated for von Willebrand disease, and genetic counseling should be offered if appropriate.
Pharmacotherapy. Several products can be used to manage von Willebrand disease, and all are used for both prophylaxis and treatment. If the disorder is caused by a partial deficiency of VWF, as in type 1, desmopressin (DDAVP and others) is effective in some individuals. Desmopressin, a synthetic derivative of the antidiuretic hormone vasopressin, causes endothelial cells to release stored VWF, stabilizes circulating FVIII, increases platelet adhesiveness, and shortens bleeding time. 18 The drug can be administered intravenously, subcutaneously, or intranasally, and is available at relatively low cost. 18 An initial trial of the drug may be done to determine its biologic duration and efficacy. If it proves ineffective or is contraindicated, factor replacement products may be used. Factor replacement products, which are derived from plasma, were initially developed to replace FVIII in people with hemophilia and led to significant improvements in morbidity and mortality in that population. Currently four factor replacement products, manufactured by different companies, are available for the treatment of von Willebrand disease. 19 These products, which are given intravenously, include both FVIII and VWF concentrates; they are relatively expensive, 19 although the costs are often covered by insurance. They may be given before menses and events that are likely to cause bleeding, such as dental, surgical, or other invasive procedures, as well as when bleeding episodes occur. Disease management that involves factor replacement products is usually best done by a hematologist who specializes in hemostasis. Most major cities have bleeding disorder centers; referral to such facilities can often lead to higher-quality care.
The management of menorrhagia in females with von Willebrand disease warrants special attention. The use of combined hormonal contraceptives is considered first-line therapy for menorrhagia for those patients who want a nonpermanent method of contraception. 10 Such contraceptives are effective because they decrease menstrual flow, suppress ovulation (thereby preventing hemorrhagic ovarian cysts), and may increase VWF and FVIII levels. 10 NSAIDs, which are often recommended for menstrual discomfort, should be avoided in patients with von Willebrand disease. 10 Acetaminophen-based products can be used instead.
More recently, antifibrinolytic agents are being used to prevent and treat both menorrhagia and other excessive bleeding episodes. 20, 21 These agents prevent plasmin from binding to fibrin, which inhibits fibrinolysis, thereby decreasing bleeding. Antifibrinolytics can be used alone or in conjunction with other medications such as desmopressin. One such agent, aminocaproic acid (Amicar), which can be given orally or intravenously, has been available for several years. Another agent, tranexamic acid, which is considerably more potent, is available in an intravenous form (Cyklokapron) and an oral form (Lysteda). The literature reports that both forms are used to treat menorrhagia, although only Lysteda has been specifically approved for that use by the U.S. Food and Drug Administration. Tranexamic acid generally costs more than aminocaproic acid. Gastrointestinal complaints such as nausea, vomiting, dyspepsia, and diarrhea are the primary adverse effects, but these can often be diminished by decreasing dosages. 20, 21 Patient education is vital and can have long-term benefits. Important educational points include advising patients to
• tell their health care providers-especially nurses providing direct care, dentists, surgeons, and gynecologists-that they have this disorder, especially if invasive procedures are anticipated. Female patients anticipating pregnancy or childbirth should alert their obstetrician-gynecologists.
• notify providers about any episodes of increased bleeding, especially if the bleeding is heavier or more prolonged than usual.
• contact providers immediately if unusual pallor or fainting occurs (these can result from anemia caused by excessive bleeding).
• choose medications for pain relief that do not increase bleeding time and avoid those that do.
• consider wearing a medical alert bracelet or necklace. • achieve and maintain a healthful weight, and exercise regularly, in order to keep muscles flexible and prevent muscle and joint damage. Stretching before exercising is also important.
• avoid contact sports (such as football and wrestling) and other activities associated with a higher risk of injury.
FURTHER RESEARCH IS NEEDED
While a great deal is known about von Willebrand disease, further research is warranted. A better understanding of the association between excessive bleeding and deficiencies or defects in VWF is needed. As an NHLBI report has stated, "Relatively few of the genetic and nongenetic determinants of VWF level have been characterized, and how they interact is poorly understood." 2 Moreover, a much better understanding of how the different types and type variants of von Willebrand disease respond to various treatments is essential for optimal management. 2 More research is also needed to better understand the influence of VWF levels with regard to vascular disorders. Since elevated concentrations of FVIII and VWF appear to "represent a prothrombotic condition," 22 several studies have sought to determine whether lowered concentrations could protect against increased clot formation. After reviewing reported cases of arterial or venous thrombosis in patients with type 1 or type 3 von Willebrand disease, Girolami and colleagues determined that such thromboses are relatively rare in this population, and suggested that the disorder possibly confers some protection. 22 But other researchers have found otherwise. In an Italian study Since each patient's bleeding propensity is different, determining the best prophylaxis and treatment regimen is often challenging.
ajnonline.com involving 24 people with type 2 von Willebrand disease and matched controls, Bilora and colleagues did not find the clotting defect in von Willebrand disease to be protective against atherosclerosis. 23 Several researchers have studied the influence of VWF (an index of endothelial damage or dysfunction) and soluble P-selectin (an index of platelet activation) on predicting the likelihood of vascular events in highrisk patients. In a study of people with atrial fibrillation who were taking aspirin, Conway and colleagues found that increased VWF levels were predictive of stroke and other vascular events while soluble P-selectin levels were not. 24 But Varughese and colleagues found the opposite to be true-VWF levels were not predictive of myocardial infarction in people with hypertension, while soluble P-selectin levels were. 25 
KIM W., REVISITED
A thorough history and physical examination revealed that, in addition to having heavy menses, Kim bruised easily and had recently experienced an episode of prolonged bleeding following a dental extraction. The NP also further investigated Kim's family history and learned of similar signs and symptoms in other relatives. Initial laboratory studies (using samples drawn during menses) showed that Kim had mild iron deficiency anemia and that her von Willebrand disease assay results were all in the lower end of the normal ranges. As a result, Kim was referred to a hematologist for a more thorough evaluation and was ultimately diagnosed with type 1 von Willebrand disease. The disorder and management strategies were discussed with Kim and her parents so that future episodes of heavy bleeding could be avoided. Since softball generally results in minimal trauma, Kim was cleared to play but was discouraged from sliding into bases. ▼ 
